Introduction
============

Acute exacerbations of COPD are characterized by a change in cough, sputum production, and respiratory symptoms from baseline that cause the patient to seek medical attention and involve increasing the dose and/or frequency of existing bronchodilator therapy. Systemic corticosteroids are also recommended in patients with more advanced COPD that may require hospitalization. Exacerbations may be mild, necessitating only outpatient therapy such as antibiotics and/or systemic steroids but often may be severe enough to require hospitalization and admission to the intensive care unit. Therefore, prevention of exacerbations is one of the most important goals of chronic obstructive pulmonary disease (COPD) management ([@b25-copd-1-345]) because of the impact on patients' daily activities and health-related quality of life (HRQoL), with these effects lasting for several weeks or months ([@b28-copd-1-345]). Frequent exacerbations also lead to a poorer recovery in terms of improvement in health status ([@b28-copd-1-345]). Furthermore, the frequency of acute exacerbation has a significant impact on the accelerated decline of lung function ([@b20-copd-1-345]) and also on healthcare costs ([@b28-copd-1-345]). Consequently, strategies for preventing COPD exacerbations may have an important effect on the natural course, cost of management, and mortality in COPD ([@b36-copd-1-345]).

In recent years, several large-scale clinical trials in COPD have analyzed the exacerbation-preventing aspects of different treatments (Niewoehner 2004; [@b47-copd-1-345]). These include inhaled bronchodilators, inhaled corticosteroids (ICSs), and a limited number of antimicrobial strategies. However, most antimicrobial strategies have been used therapeutically in the form of antibiotic treatment during an established exacerbation, apart from vaccinations against influenza and pneumococci, which can protect from these infections which are particularly dangerous for COPD patients ([@b14-copd-1-345]).

Effect of long-acting β~2~-agonists and inhaled corticosteroid in preventing COPD exacerbations
===============================================================================================

Long-acting β~2~-agonists (LABAs) have both bronchodilator and non-bronchodilator properties, whereas ICSs are potent anti-inflammatory agents ([@b12-copd-1-345]). It is, therefore, obvious that LABAs and ICSs treat different aspects of COPD ([@b12-copd-1-345]). LABAs are central in the symptomatic control of COPD ([@b2-copd-1-345]), whereas conflicting results have been reported with ICSs ([@b4-copd-1-345]; [@b7-copd-1-345]). This may reflect the fact that the inflammation in COPD is poorly suppressed by corticosteroids, with small reduction in inflammatory cells, cytokines, or proteases in induced sputum even with oral corticosteroids ([@b5-copd-1-345]), although there are some subgroups of patients (eg, those with eosinophilia) who respond very well ([@b15-copd-1-345]).

Nonetheless, findings from several clinical studies have shown that treatment with ICSs improve expiratory airflow and reduce symptoms and the rate of exacerbations associated with COPD ([@b1-copd-1-345]), and, moreover, reduce all-cause mortality in COPD ([@b46-copd-1-345]). ICSs in relatively high doses (eg, budesonide 800 μg/day or fluticasone propionate 1 mg/day) reduce exacerbations by 20%--30% and improve the health status of COPD patients by a similar amount compared with placebo ([@b35-copd-1-345]). In particular, a meta-analysis of six trials, which evaluated the long-term effects (≥ 6 months) of ICSs in stable COPD and provided information about total exacerbations, demonstrated that ICSs reduce exacerbation rates in COPD by nearly one third relative to placebo (relative risk \[RR\], 0.70; 95% CI, 0.58--0.84) ([@b1-copd-1-345]). In the ISOLDE (Inhaled Steroid in Obstructive Lung Disease in Europe) study, the major benefit of therapy was seen in those whose lung function was less than 50% of predicted; however, the number of patients having at least one exacerbation per year was reduced with ICSs irrespective of baseline lung function ([@b30-copd-1-345]). A convincing demonstration of the effectiveness of these agents in COPD patients has come from the COPE study (an investigation of COPD in the Department of Pulmonology, Enschede, the Netherlands) ([@b53-copd-1-345]). This study showed that the discontinuation of therapy with ICSs was associated with a more rapid onset and a higher risk of recurrence of exacerbations, and with a significant deterioration in aspects of HRQoL, in the majority of patients. However, 40% of subjects in the COPE study experienced no untoward effect from the withdrawal of ICSs. This finding indicates that there is an urgent need to identify which subgroups of COPD patients respond well to prolonged ICSs therapy. In any case, a recent article that has reviewed the diverse approaches to data analysis used in the randomized trials of ICSs in the treatment of COPD and their meta-analysis, has concluded that the reports that ICSs reduce COPD exacerbation rates are the result of improper statistical analysis techniques ([@b49-copd-1-345]). The only two studies that used the correct statistical approach found insignificant effects with these drugs. It is not a surprise, therefore, that the evaluation of a cohort of newly treated COPD patients formed from the Administrative Databases of Saskatchewan Health documented that ICSs do not seem to be beneficial in preventing the risk of a first exacerbation of COPD ([@b19-copd-1-345]). Interestingly, a recent paper has documented that immortal time bias cannot account for the risk reduction associated with ICSs exposure in observational studies ([@b31-copd-1-345]). This finding is strengthened by the observed relationship between increased regularity of ICSs prescriptions and reductions in event rates.

Although LABAs have been shown to reduce exacerbation rates of COPD, the magnitude of the effect appears modest at best. Published trials reveal that salmeterol is the only LABA with a significant effect on the rate of exacerbations. In a 1-year study comparing salmeterol with placebo, salmeterol significantly reduced the mean number of exacerbations per patient by 20% and the mean number of exacerbations requiring oral corticosteroids per patient by 29% ([@b10-copd-1-345]). Recently, it has been documented that the addition of salmeterol to existing treatment in patients with a history of COPD exacerbations and poor reversibility of airflow obstruction reduces exacerbations in patients who comply with treatment ([@b48-copd-1-345]). On the contrary, formoterol, in twice daily doses, failed to show such an effect in two other trials ([@b9-copd-1-345]; [@b50-copd-1-345]), although a subsequent study has documented that it can influence exacerbation surrogates, for example "bad days" ([@b18-copd-1-345]). Salmeterol has been shown in several model systems to reduce inflammatory cell activation, to reduce formation of edema and to enhance edema clearance, and to mitigate epithelial damage induced by bacteria ([@b43-copd-1-345]). Whether these effects have any clinical importance remains to be determined, but they may account for its ability to reduce frequency of exacerbations of COPD. Formoterol may have similar non-bronchodilator effects; however, studies are needed to document these effects.

Pharmacological rationale for combining long-acting β~2~-agonists and inhaled corticosteroid in COPD
====================================================================================================

Interaction at the molecular level between ICSs and LABAs
---------------------------------------------------------

Combining two therapies that possess different modes of action could be expected to have a greater benefit in the management of COPD. There is an exciting possibility that the potential benefit in combining ICSs and LABAs might be due to a synergistic interaction. However, the basic molecular mechanism of such an interaction has still to be fully identified. Recent in vitro and in vivo evidence suggest a mechanistic interaction at the molecular level between ICSs and LABAs. Corticosteroids have been shown to up-regulate the β~2~-adrenoceptor in the human airways, which in turn may provide more receptors for β~2~-agonists to activate ([@b34-copd-1-345]; [@b3-copd-1-345]). At the same time, LABAs may potentiate the molecular mechanism of corticosteroid actions by increasing the nuclear translocation of glucocorticoid receptors (GRs) and thus causing an additive or sometimes synergistic suppression of inflammatory mediator release ([@b24-copd-1-345]; [@b32-copd-1-345]; [@b39-copd-1-345], [@b40-copd-1-345]). Similar interactions between ICSs and LABAs in vivo are a likely explanation for the effects seen in the study of [@b6-copd-1-345] documenting that the combination of inhaled salmeterol and fluticasone propionate significantly reduced the absolute numbers of biopsy (CD45^+^) leukocytes, CD8^+^ cells, and CD4^+^ cells together with decreases in cells expressing genes for the proinflammatory mediators IFN-γ and TNF-α. In the complementary airway compartment sampled by induced sputum, combination treatment significantly reduced sputum differential neutrophils and total eosinophils. Furthermore, in vitro studies suggest that the addition of a LABA to an ICS may counter some of the potential negative effects of the corticosteroid ([@b52-copd-1-345]) or alternatively, some of those elicited by LABA ([@b45-copd-1-345]).

Increasing compliance
---------------------

In addition to the complementary interaction of LABAs and ICSs at the molecular level, the delivery of these medications together in a single device may also help simplify treatment regimens and improve patient adherence ([@b12-copd-1-345]). It is widely recognized that adherence to treatment of chronic obstructive airways diseases declines as the regime becomes more complicated, either by increasing the number of medications and/or the number of daily doses ([@b17-copd-1-345]; [@b16-copd-1-345]). As a result, improved compliance would be expected to occur through the use of a single combination inhaler simply because of the reduction in the number of medications and actuations required with such a regime. In particular, it would be expected that the use of combination therapy should improve compliance with ICS therapy as its use is linked with LABA therapy, which patients are more likely to take because of the greater symptomatic benefit.

Enhanced respiratory cytoprotection against viral and bacterial infection
-------------------------------------------------------------------------

Because of the above effects, it is not unexpected that long-term use of ICSs with LABAs may be associated with a reduction in COPD exacerbations ([@b12-copd-1-345]). However, the capacity of both ICSs and LABAs to reduce the total number of bacteria adhering to the respiratory mucosa in a concentration-dependent manner without altering the bacterial tropism for mucosa, and to preserve ciliated cells, is important in this context ([@b22-copd-1-345]). ICSs and LABAs, when administered together at low concentrations, exhibited a synergistic effect with respect to the preservation of ciliated cells, showing a trend toward reduced damage and a significant preservation of the number of ciliated cells compared with either agent alone at the same concentrations. This result may have clinical significance as it is thought that ciliated cells are the most sensitive to damage by bacterial infection ([@b51-copd-1-345]). It is well-known that airway colonization and chronic infection contribute to progressive pulmonary damage in COPD patients via the action of proinflammatory substances in what is known as the "vicious circle theory" ([@b56-copd-1-345]). Recently, the synergistic effects of salmeterol and fluticasone in human rhinovirus-induced proinflammatory cytokine production have also been documented ([@b23-copd-1-345]). Rhinoviruses are implicated in many acute exacerbations of COPD, perhaps by inducing proinflammatory cytokines ([@b44-copd-1-345]).

Effect of combination therapy in preventing COPD exacerbations
==============================================================

The efficacy of combination therapy with ICSs and LABAs delivered via a single inhaler to COPD patients has repeatedly been documented ([Table 1](#t1-copd-1-345){ref-type="table"}). In particular, the impact on acute exacerbations of long-term treatments with combined therapy is shown in [Figures 1](#f1-copd-1-345){ref-type="fig"} and [2](#f2-copd-1-345){ref-type="fig"}, and [Table 2](#t2-copd-1-345){ref-type="table"}. It is very important to also mention that the definition of exacerbation and the patient population enrolled in these studies are not uniform ([Table 3](#t3-copd-1-345){ref-type="table"}), and these facts have to be taken in consideration when analyzing their results.

In a multicenter, randomized, placebo-controlled study, [@b27-copd-1-345] compared the efficacy and safety of fluticasone propionate (250 μg) and salmeterol (50 μg), when administered twice daily together in a single device for 6 months, with that of placebo and the individual agents alone in patients with COPD. This study was unable to observe significant differences among treatment groups in the number of exacerbations or the time to first exacerbation. However, this study was of short duration and was designed and powered to evaluate the treatment effect on FEV~1~, which was the primary measure of efficacy, rather than to evaluate the rates of exacerbations.

In a study with a similar design but evaluating the higher dose formulation of this combination therapy, fluticasone propionate (500 μg) with salmeterol (50 μg) twice daily given for 6 months ([@b33-copd-1-345]), there were no statistically significant differences between treatment groups in time to exacerbation. This study also demonstrated no difference in the number of participants who exacerbated once (placebo: 8.8%; salmeterol: 5.6%; fluticasone: 10.1%; fluticase/salmeterol combination \[FSC\]: 8.5%), but no p values were presented. Also this study was of short duration and was designed and powered to evaluate the treatment effect on FEV~1~, which was the primary measure of efficacy, rather than to evaluate the rates of exacerbations.

The TRISTAN study ([@b10-copd-1-345]), a randomized controlled trial over 1 year of combination treatment with salmeterol (50 μg) and fluticasone (500 μg) administered together in a single device twice daily versus each of the components alone and versus placebo, enrolled patients with a baseline FEV~1~ before bronchodilation that was 25%--70% of that predicted. In this study, the rate of exacerbations requiring medical intervention, defined as a worsening of COPD symptoms that required treatment with antibiotics or oral corticosteroids, or both, fell by 25% in the combination group and by 20% and 19% in the salmeterol and fluticasone groups, respectively, compared with placebo. In particular, there was a significant difference in the mean exacerbation rate per participant per year in favor of the combination therapy when compared with placebo (FSC: 0.97 vs placebo: 1.30, p\<0.0001), but, interestingly, differences among the three active treatment arms were small and not statistically significant. The treatment effect was more pronounced in patients with severe disease (ie, a baseline FEV~1~ \<50% of predicted), who showed a 30% reduction with combination therapy compared with placebo, compared with a 10% reduction in patients who had a baseline FEV~1~ greater than 50% of predicted. However, this beneficial effect was also seen for exacerbations treated with oral corticosteroids, which have conventionally been thought to be more severe episodes. The combination therapy was associated with an approximate 39% reduction in the number of this type of exacerbations compared with placebo (0.46 vs 0.76 exacerbations per year, p\<0.0001) but, again, the differences between FSC and salmeterol or fluticasone were not significant. It is worth mentioning that the TRISTAN was longer, but still based on FEV~1~. Hence, the ability to observe exacerbation differences may have been helped by study duration.

In a study using a design similar to that of the TRISTAN study but including patients with an FEV~1~ below 50% predicted, [@b50-copd-1-345] compared the effects of two inhalations twice daily of either budesonide/formoterol combination (BFC) 160/4.5 μg (delivered dose) in a single inhaler, budesonide 200 μg (metered dose), formoterol 4.5 μg, or placebo for 12 months. Data from this study demonstrate a significant reduction in the number of severe exacerbations by 24% in the BFC group vs placebo, 23% vs formoterol, and 11% vs budesonide. This reflects a mean reduction in the mean annual exacerbation rates of 0.42 (95% CI 0.14--0.70), 1.84--1.42 exacerbations per year when combination therapy was used. Compared with placebo, both BFC and budesonide significantly reduced the number of oral steroid courses used in association with exacerbations (31% and 29%, respectively, compared with 3% for formoterol vs placebo). In addition, BFC significantly reduced the number of oral steroid courses compared with formoterol (−28%). Mild exacerbations were also significantly reduced on BFC when compared with placebo (−62%) and budesonide (−35%), but not with formoterol (−15%).

In another study investigating BFC, [@b9-copd-1-345] studied patients who initially received formoterol alone (9 μg delivered dose twice daily) and a short course of oral prednisolone (30 mg once daily) for 2 weeks before randomization. The patients were subsequently randomized to twice daily inhaled BFC 320/9 μg (delivered dose), budesonide 400 μg (metered dose), formoterol 9 μg, or placebo for 12 months, BFC prolonged time to first exacerbation requiring medical intervention, defined as a need for antibiotics and/or oral corticosteroids and/or hospitalization due to respiratory symptoms, compared with all other treatments. Hazard rate analysis showed that the risk of having an exacerbation while being treated with BFC was reduced by 22.7%, 29.5%, and 28.5% vs budesonide, formoterol, and placebo, respectively. The exacerbation rate with BFC was reduced compared with placebo (23.6%) and formoterol (25.5%) but not with budesonide alone (13.6%). Neither budesonide nor formoterol affected either measure of exacerbation compared with placebo. Furthermore, BFC prolonged the time to first course of oral corticosteroids after randomization; risk reductions were 32.7% and 33.8% vs budesonide and formoterol, respectively, and 42.3% vs placebo. BFC also reduced the rate of oral corticosteroid courses by 28.2%, 30.5%, and 44.7% vs budesonide, formoterol, and placebo, respectively; budesonide alone reduced the number of oral corticosteroid courses compared with placebo but formoterol did not.

Considerations on the role of the combination therapy in preventing COPD exacerbations
--------------------------------------------------------------------------------------

Data of three large studies ([@b10-copd-1-345], [@b9-copd-1-345]; [@b50-copd-1-345]) that have examined the effects of a combination of LABA and ICS on the risk of developing exacerbation in COPD have shown that the patients receiving combination therapy were less likely to report an exacerbation than those receiving the LABA alone. Nevertheless, a recent Cochrane review ([@b37-copd-1-345]) concluded that there were conflicting results when the different combination therapies were compared with the single components alone. In particular, the results of the studies showed that BFC and FSC were effective and reduced the frequency of exacerbations compared with dummy medication to a level of three quarters of the previous rates, with one exacerbation prevented every 2--4 years in the participants in the clinical trials. When the combination treatment was compared with one of the component drugs given as single treatments, BFC was better than its component LABA at preventing the frequency of exacerbations, but FSC did not show a significant advantage over LABA. Recently, two different reviews ([@b26-copd-1-345]; [@b11-copd-1-345]), which have evaluated the applicability and clinical relevance of number needed to treat (NNT) analysis for determining the effectiveness of combination therapies against COPD exacerbations, have calculated that for every 100 patients treated with BFC for 1 year, between 42 and 47 exacerbations requiring medical intervention would be prevented vs LABA therapy alone, whereas for every 100 patients treated with FSC for 1 year, only 7 exacerbations would be prevented vs LABA alone ([Table 2](#t2-copd-1-345){ref-type="table"}). It should be noted, however, that the NNT value relating to FSC should be interpreted with caution as there was no significant difference between FSC and salmeterol alone (p=0.345 for treatment ratios for combination vs salmeterol therapy). This means that the hypothetical 95% CI would include infinity and that an NNT of infinity should be more appropriately applied to the difference between the two treatments, which indicates no true net clinical benefit of FSC over salmeterol alone.

In any case, in a recent study investigating the effect withdrawal of fluticasone from patients with severe COPD (FEV~1~ \<50% predicted) using FSC (COSMIC study) for 3 months, [@b57-copd-1-345] demonstrated an acute and sustained decrease in FEV~1~, increase in symptoms, and an increase in mild exacerbations in patients treated with salmeterol alone compared with those who continued treatment with FSC over the one year of the study. These results emphasize the key role of ICSs in managing COPD.

The conflicting findings between the results of the different studies may be accounted for by dissimilar study designs. In particular, definitions of exacerbation that have been used in the examined studies have been rather different ([Table 3](#t3-copd-1-345){ref-type="table"}). For example, in Mahler's study ([@b33-copd-1-345]), exacerbation was defined by treatment (mild = increased use of salbutamol; moderate = use of either oral antibiotics and/or corticosteroids; severe = hospitalization). In the Szafranski's study ([@b50-copd-1-345]), the definition of mild exacerbation was a day with ≥ 4 inhalations of reliever medication above the mean run-in use, whereas that of severe exacerbation was a requirement for oral steroids and/or antibiotics and/or hospitalization due to respiratory symptoms. In the TRISTAN study ([@b10-copd-1-345]), exacerbations were defined a priori as a worsening of COPD symptoms that required treatment with antibiotics or oral corticosteroids, or both. Episodes that required corticosteroid treatment or hospital admission were noted separately. [@b41-copd-1-345] correctly highlighted that considerable heterogeneity in the aetiology and manifestation of COPD exacerbations makes identification and quantification of defining symptoms extremely difficult. However, with the emergence of a number of drugs designed or developed specifically to treat COPD and associated exacerbations, the absence of a uniform definition is a significant issue. In fact, the choice of definition can significantly affect study outcomes, with varying criteria likely to result in different levels of demonstrated treatment success. Furthermore, emerging data confirm that exacerbation is a term not easily understood by patients, who prefer to use simpler words such as "crisis" ([@b28-copd-1-345]).

It is also interesting to stress that there was some difference in the patient populations enrolled in the studies described above. Patients enrolled in the TRISTAN study ([@b10-copd-1-345]) had to have suffered from at least one episode of acute COPD symptom exacerbation per year in the previous 3 years, and at least one exacerbation in the year immediately before trial entry that required treatment with oral corticosteroids, antibiotics, or both. In the Szafranski study ([@b50-copd-1-345]), patients had to have suffered from at least one severe (use of oral corticosteroids and/or antibiotics and/or hospitalization due to respiratory symptoms) COPD exacerbation within 2±12 months before the first clinic visit. Moreover, the mean pre-trial FEV~1~ was 45% predicted in the TRISTAN study ([@b10-copd-1-345]) and 36% predicted in the Szafranski's study ([@b50-copd-1-345]). Moreover, the mean total exacerbation rate per patient per year under placebo was 1.30 in the TRISTAN study ([@b10-copd-1-345]) and 1.9 in the Szafranski study ([@b50-copd-1-345]). This differences indicate that the Szafranski's study ([@b50-copd-1-345]) probably enrolled patients with more severe disease or, at least, with a higher possibility of suffering from acute exacerbation. In fact, also in the Calverley study ([@b9-copd-1-345]), the mean pre-trial FEV~1~ was 36% predicted and the mean total exacerbation rate per patient per year under placebo was 1.80. As correctly highlighted by [@b9-copd-1-345], the more severe disease in the patients enrolled in BFC studies is the likely explanation of the greater number of episodes that they observed compared with other studies, a difference that increased the power of the study to detect an effect of treatment. It is also important to highlight that the authors of the three studies did not report the number of exacerbations in the year before the enrolment in the studies. This is a real lack of information because, as recently documented by [@b21-copd-1-345], annual exacerbation frequency remains constant over time.

As [@b42-copd-1-345] stated in his editorial comment on the Calverley paper ([@b9-copd-1-345]), the data of the combination therapy trials in COPD seem to indicate that patients experiencing more severe exacerbations benefit the most from combination therapy, whereas, if the definition of a (mild) exacerbation for clinical trials also includes aggravation of symptoms, such as in the paper by [@b50-copd-1-345], the relative effect of a long-acting bronchodilator might be more pronounced. This clearly highlights the importance of definitions of exacerbations for clinical trials and calls for studies comparing the effect of maximal bronchodilation with, for example, the combination of LABAs with long-acting anticholinergics (LAMAs) in COPD with mild and severe exacerbations as an outcome. In effect, some studies are documenting the clinical value of combining a LABA with a LAMA in COPD ([@b13-copd-1-345]; [@b54-copd-1-345], [@b55-copd-1-345]), although the information of the impact of such a type of combination on exacerbations is still lacking.

Borrowing Jones' opinion ([@b29-copd-1-345]), we believe that there are a number of possible mechanisms to account for the apparent additive effect of inhaled combination therapy with ICSs and LABAs in preventing exacerbations and to explain the discrepancies observed between the studies. It is likely that: (1) the individual drugs were not at the top of their dose--response curve for this outcome; (2) they have different, and additive, mechanisms of action, which can also be linked to the specific compound; or (3) the different agents were preventing different types of exacerbation. [@b29-copd-1-345] has highlighted that an operational definition based upon a worsening of symptoms and the treatment required (moderate exacerbations are those that can be treated with oral corticosteroids and/or antibiotics, severe exacerbations are those requiring hospital admission) does not identify the type of exacerbation. This emphasizes again the importance for the need of a uniform definition of COPD exacerbation for clinical trials in order to reach more solid conclusions.

Whatever the case may be, it must be emphasized that a treatment regimen with administration of an ICS and LABA in a single inhaler prolongs the time to a first COPD exacerbation, compared with treatment with the single components in patients with an FEV~1~ \<50% predicted ([@b9-copd-1-345]). Intriguingly, this finding has been observed with BFC ([@b9-copd-1-345]), but not with FSC ([@b10-copd-1-345]). The prolonged time to first exacerbation may delay the deterioration of the disease and help maintain health status and patient well-being. It is an important outcome because it indicates that following aggressive treatment of an acute exacerbation with an oral corticosteroid, therapy with an ICS/LABA combination may better control the disease than treatment with bronchodilator alone. In particular, as highlighted by [@b8-copd-1-345], combining treatments is certainly something to be considered in patients who have reported exacerbations on a regular basis but have not yet received ICS or LABA therapy in combination, although there are concerns about the increased risk of side-effects and cost of using LABA/ICS therapy in COPD.
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**Notes:** PLA, placebo; LABA, salmeterol 50 μg bid or formoterol 12 μg bid; ICS, fluticasone propionate 500 μg bid or budesonide 400 μg bid; LABA/ICS, salmeterol 50 μg/fluticasone 500 μg bid or formoterol 12 μg/budesonide 400 μg bid. \* difference between combination treatment and single compound treatment and/or PLA statistically significant (p\<0.05); § difference between single compound treatment and PLA statistically significant (p\<0.05). Data from [@b10-copd-1-345] (TRISTAN); [@b9-copd-1-345]; [@b50-copd-1-345].](copd-1-345f1){#f1-copd-1-345}

![Rate of exacerbations requiring oral corticosteroids.\
**Notes:** PLA, placebo; LABA, salmeterol 50 μg bid or formoterol 12 μg bid; ICS, fluticasone propionate 500 μg bid or budesonide 400 μg bid; LABA/ICS, salmeterol 50 μg/fluticasone 500 μg bid or formoterol 12 μg/budesonide 400 μg bid. \* difference between combination treatment and single compound treatment and/or PLA statistically significant (p\<0.05); § difference between single compound treatment and PLA statistically significant (p\<0.05). Data from [@b10-copd-1-345] (TRISTAN); [@b9-copd-1-345]; [@b50-copd-1-345].](copd-1-345f2){#f2-copd-1-345}

###### 

Long-term effect of combination therapy in COPD

  Study                               Treatment (μg bid)[a](#tfn1-copd-1-345){ref-type="table-fn"}   N     Duration (weeks)   Baseline FEV~1~(% pred)   Primary outcome(s)
  ----------------------------------- -------------------------------------------------------------- ----- ------------------ ------------------------- ----------------------------
  **Fluticasone/salmeterol (FSC)**                                                                                                                      
  [@b27-copd-1-345]                   FSC 250/50                                                     178   24                 41%                       Changes in FEV~1~
                                      FP 250                                                         183                      42%                       
                                      SAL 50                                                         177                      42%                       
                                      PLA                                                            185                      42%                       
  [@b33-copd-1-345]                   FSC 500/50                                                     165   24                 41%                       Changes in FEV~1~
                                      FP 500                                                         168                      41%                       
                                      SAL 50                                                         160                      40%                       
                                      PLA                                                            181                      41%                       
  [@b10-copd-1-345] (TRISTAN study)   FSC 500/50                                                     358   52                 45%                       Changes in FEV~1~
                                      FP 500                                                         374                      45%                       
                                      SAL 50                                                         372                      44%                       
                                      PLA                                                            361                      44.2                      
  **Budesonide/formoterol (BFC)**                                                                                                                       
  [@b50-copd-1-345]                   BFC 400/12                                                     208   52                 36%                       Changes in FEV~1~
                                      BUD 400                                                        198                      37%                       
                                      FORM 12                                                        201                      36%                       
                                      PLA                                                            205                      36%                       Number of exacerbations
  [@b9-copd-1-345]                    BFC 400/12                                                     254   52                 36%                       Changes in FEV~1~
                                      BUD 400                                                        257                      36%                       
                                      FORM 12                                                        255                      36%                       
                                      PLA                                                            256                      36%                       Time to first exacerbation

All doses are reported as metered doses.

**Abbreviations:** BFC, budesonide/formoterol combination; BUD, budesonide; FORM, formoterol; FP, fluticasone propionate; FSC, fluticasone/salmeterol combination; PLA, placebo; SAL, salmeterol.

###### 

Absolute and relative risk reductions for exacerbations of COPD requiring medical intervention with number needed to treat in three randomized and double-blind multinational trials

  Treatment                                    12 month frequency of exacerbation (mean rate/patient/year)   Absolute risk reduction   Relative risk reduction (combination vs LABA)   NTT            Reference   
  -------------------------------------------- ------------------------------------------------------------- ------------------------- ----------------------------------------------- -------------- ----------- -------------------
  Fluticasone/salmeterol (TRISTAN, n = 1456)   0.97                                                          1.04                      0.07                                            0.067 (6.7%)   14          [@b10-copd-1-345]
  Budesonide/formoterol (n = 812)              1.42                                                          1.84                      0.42                                            0.23 (23%)     2.4         [@b50-copd-1-345]
  Budesonide/formoterol (n = 1002)             1.38                                                          1.85                      0.47                                            0.25 (25%)     2.1         [@b9-copd-1-345]

Data from [@b11-copd-1-345].

**Abbreviations:** LABA, long-acting β~2~-agonist; NNT, number needed to treat.

###### 

Definitions of COPD exacerbation used in combination therapy studies

  Study                               Definition
  ----------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@b27-copd-1-345]                   Defined by treatment, with moderate exacerbations requiring treatment with antibiotics and/or corticosteroids, and severe exacerbations requiring hospitalization)
  [@b33-copd-1-345]                   Defined by treatment (mild = increased use of salbutamol; moderate = use of either oral antibiotics and/or corticosteroids; severe = hospitalization)
  [@b10-copd-1-345] (TRISTAN study)   Worsening of COPD symptoms that required treatment with antibiotics, oral corticosteroids, or both
  [@b50-copd-1-345]                   Mild: a day with ≥ 4 inhalations of reliever medication above the mean run-in use; severe: requirement for oral steroids and/or antibiotics and/or hospitalization due to respiratory symptoms
  [@b9-copd-1-345]                    Event requiring medical intervention (oral antibiotics and/or corticosteroids or hospitalization) due to respiratory symptoms
